Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High – Still a Buy?

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) reached a new 52-week high during trading on Friday . The company traded as high as $49.70 and last traded at $46.63, with a volume of 756709 shares. The stock had previously closed at $46.14.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, Wells Fargo & Company assumed coverage on Definium Therapeutics in a research note on Monday, July 27th. They set an “overweight” rating and a $68.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $54.85.

Definium Therapeutics Price Performance

The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The business’s 50-day simple moving average is $37.45 and its 200 day simple moving average is $25.72. The firm has a market capitalization of $4.48 billion, a P/E ratio of -18.04 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Sell-side analysts forecast that Definium Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider directly owned 320,571 shares of the company’s stock, valued at $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 in the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DFTX. Commodore Capital LP grew its holdings in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Definium Therapeutics during the third quarter valued at about $4,337,000. Two Sigma Investments LP raised its stake in shares of Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Definium Therapeutics by 62.6% during the third quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock worth $3,516,000 after purchasing an additional 114,805 shares during the period. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.